EVMN (EVMN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

EVMN (EVMN) closed at USD 5.77 on 2026-10-14, a change of -71.5 % over the past year, with a market capitalization of USD 215.21M.

EVMN recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

EVMN key figures

Previous close

USD 5.77 (2026-10-14)

1-year change

-71.5 %

Market cap

USD 215.21M

Enterprise value

USD 23.05M

P/E ratio (trailing)

-1.58

P/E ratio (forward)

-1.67

EPS (trailing)

-3.75

EPS (forward)

-3.54

PEG ratio

n/a

Price to book

0.78

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.64

Employees

48

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About EVMN

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for EVMN and compare it with other stocks.